MBX Biosciences announces positive Phase 1 results of their drug for hypoPARAthyroidism
November 17, 2023
We are pleased to announce positive results from our Phase 1 Study of MBX 2109, our long-acting parathyroid hormone (PTH) peptide prodrug in development for the treatment of hypoparathyroidism (HP). Learn more about the data presented in a late-breaking oral presentation at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting: https://lnkd.in/eUVBc_i8 #ASBMR2023